Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Depreciation and Depletion (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Depreciation and Depletion data on record, last reported at $10000.0 in Q3 2025.

  • For Q3 2025, Depreciation and Depletion changed 0.0% year-over-year to $10000.0; the TTM value through Sep 2025 reached $39000.0, up 8.33%, while the annual FY2024 figure was $38000.0, 8.57% up from the prior year.
  • Depreciation and Depletion reached $10000.0 in Q3 2025 per GANX's latest filing, roughly flat from $10000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $17139.0 in Q2 2023 and bottomed at $2158.0 in Q2 2021.
  • Average Depreciation and Depletion over 5 years is $8239.7, with a median of $9000.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: surged 433.09% in 2022, then crashed 47.49% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $5785.0 in 2021, then surged by 34.35% to $7772.0 in 2022, then rose by 15.8% to $9000.0 in 2023, then grew by 11.11% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $10000.0 in Q3 2025, $10000.0 in Q2 2025, and $9000.0 in Q1 2025.